Systemic timolol exposure following topical application to infantile hemangiomas

TY - JOUR

T1 - Systemic timolol exposure following topical application to infantile hemangiomas

AU - Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.)

AU - Drolet, Beth A.

AU - Boakye-Agyeman, Felix

AU - Harper, Barrie

AU - Holland, Kristen

AU - Lewandowski, Andrew

AU - Stefanko, Nicole

AU - Melloni, Chiara

AU - Furda, Gary

AU - Benjamin, Danny

AU - Capparelli, Edmund

AU - Kearns, Gregory L.

AU - Paul, Ian M.

AU - Hornik, Christoph

AU - Wade, Kelly

N1 - Funding Information: Funding sources: Supported under National Institute of Child Health and Human Development contract HHSN275201000003I for the Pediatric Trials Network (principal investigator, Danny Benjamin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Disclosure: Dr Drolet reports an investigator-initiated trial examining the safety of oral propranolol for treatment of infantile hemangioma that was sponsored by Pierre Fabre. She is owner and co-founder of Peds Derm Development Group, LLC. Dr Boakye-Agyeman, Mr Harper, Dr Holland, Dr Lewandowski, and Dr Stefanko have no conflicts of interest to disclose.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85076207769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076207769&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2019.02.029

DO - 10.1016/j.jaad.2019.02.029

M3 - Article

C2 - 30790601

AN - SCOPUS:85076207769

VL - 82

SP - 733

EP - 736

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -